1. Home
  2. YCBD vs SILO Comparison

YCBD vs SILO Comparison

Compare YCBD & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo cbdMD Inc.

YCBD

cbdMD Inc.

HOLD

Current Price

$0.75

Market Cap

7.9M

Sector

Health Care

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.49

Market Cap

7.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
YCBD
SILO
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.2M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
YCBD
SILO
Price
$0.75
$0.49
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
382.0K
3.2M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.98
EPS
N/A
N/A
Revenue
N/A
$72,102.00
Revenue This Year
$12.70
$1.86
Revenue Next Year
$7.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.22
52 Week High
$2.56
$1.18

Technical Indicators

Market Signals
Indicator
YCBD
SILO
Relative Strength Index (RSI) 48.97 63.39
Support Level $0.63 $0.29
Resistance Level $0.80 $0.74
Average True Range (ATR) 0.08 0.06
MACD 0.01 0.01
Stochastic Oscillator 65.29 53.11

Price Performance

Historical Comparison
YCBD
SILO

About YCBD cbdMD Inc.

cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: